Highlights
NASDAQ: TGTX       Tg Therapeuticscmn
Last Price Today's Change   Day's Range   Trading Volume
13.50   -0.05 (0.37%)  13.46 - 13.80  2,025,400

Overview

 
Avg Volume (4 weeks):2,405,305
4 Weeks Range:10.34 - 14.89
4 Weeks Price Volatility (%):
69.45%
52 Weeks Range:3.87 - 14.89
52 Weeks Price Volatility (%):
87.39%
Average Price Target: 8.00
Price Target Upside/Downside: -5.50

Headlines



No recent Headlines for this stock.


Business Background

TG Therapeutics Inc is a U.S. biopharmaceutical company focused on the development and commercialization of B-cell malignancies and autoimmune disease treatments. The pipeline includes two treatments targeting hematological malignancies and autoimmune diseases: TG-1101 (ublituximab), a glycoengineered monoclonal antibody; and TGR-1202, an orally available PI3K delta inhibitor for various hematologic malignancies. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 now entering clinical development for autoimmune disorders. The company also has preclinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies.

  Be the first to like this.
 


 

1843  6298  540  225 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 VXX 14.24+0.75 
 EEM 44.60-0.36 
 SPY 328.77-2.95 
 INTC 68.47+5.15 
 AMD 50.35-1.36 
 CHK 0.558-0.015 
 F 9.00-0.14 
 NIO 4.66-0.26 
 AVP 5.60-0.05 
 GE 11.71-0.06 
Partners & Brokers